Current approaches to the management of brain metastases
JH Suh, R Kotecha, ST Chao, MS Ahluwalia… - Nature reviews Clinical …, 2020 - nature.com
Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …
approached as a single disease entity given the uniform association with poor clinical …
Brain metastases
AS Achrol, RC Rennert, C Anders, R Soffietti… - Nature Reviews …, 2019 - nature.com
An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
[HTML][HTML] Mechanisms of acquired resistance to first-and second-generation EGFR tyrosine kinase inhibitors
Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …
Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity
Purpose: Approximately one-third of patients with non–small cell lung cancer (NSCLC)
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
harboring tumors with EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutations (EGFRm) …
Management of brain metastases according to molecular subtypes
R Soffietti, M Ahluwalia, N Lin, R Rudà - Nature Reviews Neurology, 2020 - nature.com
The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
Acquired resistance to TKIs in solid tumours: learning from lung cancer
The use of advanced molecular profiling to direct the use of targeted therapy, such as
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …
tyrosine kinase inhibitors (TKIs) for patients with advanced-stage non-small-cell lung cancer …
Treatment of brain metastases
X Lin, LM DeAngelis - Journal of clinical oncology, 2015 - ascopubs.org
Brain metastases (BMs) occur in 10% to 20% of adult patients with cancer, and with
increased surveillance and improved systemic control, the incidence is likely to grow …
increased surveillance and improved systemic control, the incidence is likely to grow …
Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid
Purpose Cancer spread to the central nervous system (CNS) often is diagnosed late and is
unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS …
unresponsive to therapy. Mechanisms of tumor dissemination and evolution within the CNS …
[HTML][HTML] First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain …
Introduction Metastatic spread to the brain is common in patients with non–small cell lung
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials …
cancer (NSCLC), but these patients are generally excluded from prospective clinical trials …
[HTML][HTML] Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non–small-cell lung cancer
AJ Weickhardt, B Scheier, JM Burke, G Gan… - Journal of Thoracic …, 2012 - Elsevier
Introduction: Many patients with oncogene-driven non–small-cell lung cancer (NSCLC)
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …
treated with tyrosine kinase inhibitors experience limited sites of disease progression. This …